ReWalk developer Argo to raise $50m on Nasdaq


The enthusiastic publicity about ReWalk's FDA approval could help the IPO.

Yokne'am based Argo Medical Technologies will attempt to raise $40-50 million on Nasdaq at a company value of $250-300 million. The move comes as the company received US Food and Drug Administration approval for using its ReWalk device at home and in the community. ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with Spinal Cord Injury (SCI) to stand upright and walk.

Wall Street is not very sympathetic to biomedical IPOs at present but the enthusiastic publicity and buzz created by ReWalk's FDA approval could help the Israeli company overcome the problem.

Published by Globes [online], Israel business news - - on June 30, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017